By Nancy Lapid

(Reuters) – The next is a abstract of some latest research on COVID-19. They embrace analysis that warrants additional examine to corroborate the findings and that has but to be licensed by peer assessment.

Weight problems could weaken vaccine safety within the by no means contaminated

Extreme weight problems could weaken the effectiveness of COVID-19 vaccines in those that have by no means been contaminated with the coronavirus, in response to a small Turkish examine.

Amongst these within the examine with out earlier SARS-CoV-2 an infection who had obtained the Pfizer/BioNTech vaccine, sufferers with extreme weight problems had antibody ranges greater than thrice decrease than normal-weight people. Amongst recipients of Sinovac Biotech’s CoronaVac, these with extreme weight problems and no historical past of prior an infection had antibody ranges 27 instances decrease than regular weight individuals, in response to knowledge being offered this week on the European Congress on Weight problems in Maastricht, Netherlands. By comparability, within the 70 volunteers with a earlier coronavirus an infection, antibody ranges had been comparable in individuals with and with out extreme weight problems.

For the examine, researchers had in contrast immune responses to vaccines in 124 volunteers with extreme weight problems – outlined as a physique mass index of 40 or greater – and 166 normal-weight people (BMI lower than 25). General, 130 contributors had obtained two doses of the Pfizer/BioNTech mRNA vaccine and 160 had obtained two doses of Sinovac’s inactivated-virus vaccine.

Whereas two doses of the Pfizer/BioNTech vaccine “could generate considerably extra antibodies than CoronaVac in individuals with extreme weight problems… additional analysis is required to find out whether or not these greater antibody ranges present larger safety in opposition to COVID-19,” examine chief Volkan Demirhan Yumuk from Istanbul College mentioned in an announcement

Unvaccinated Omicron sufferers in danger from variants

An infection with the Omicron variant of the coronavirus can considerably enhance the immune system’s capability to guard in opposition to different variants, however solely in individuals who have been vaccinated, South African researchers have discovered.

In unvaccinated individuals, an Omicron an infection gives solely “restricted” safety in opposition to reinfection, they reported on Friday in Nature. In 39 sufferers who had Omicron infections – together with 15 who had been immunized with vaccines from Pfizer/BioNTech or Johnson & Johnson (NYSE:) – the researchers measured the power of immune cells to neutralize not solely Omicron but additionally earlier variants. At a mean of 23 days after Omicron signs began, unvaccinated sufferers had 2.2-fold decrease neutralization of the primary model of the Omicron variant in comparison with vaccinated individuals, 4.8-fold decrease neutralization of the second Omicron sublineage, 12-fold decrease Delta neutralization, 9.6-fold decrease Beta variant neutralization, and 17.9-fold decrease neutralization of the unique SARS-CoV-2 pressure. The hole in immunity between unvaccinated and vaccinated people “is regarding,” the researchers mentioned.

“Particularly as immunity wanes, unvaccinated people post-Omicron an infection are prone to have poor cross-protection in opposition to current and presumably rising SARS-CoV-2 variants,” they mentioned. “The implication could also be that Omicron an infection alone shouldn’t be enough for defense and vaccination needs to be administered even in areas with excessive prevalence of Omicron an infection to guard in opposition to different variants.”

Completely different vaccines shield nicely in opposition to extreme COVID-19

Whereas the mRNA vaccines from Pfizer/BioNTech and Moderna (NASDAQ:) generate greater antibody ranges to guard in opposition to SARS-CoV-2 an infection, AstraZeneca (NASDAQ:)’s viral-vector-based vaccine gives equal safety in opposition to hospitalization and dying from COVID-19, in accordance a assessment of dozens of research.

A panel of consultants in Southeast Asia reviewed 79 earlier research for a examine funded by AstraZeneca. Each varieties of vaccines confirmed over 90% efficacy in opposition to hospitalization and dying, the panelists mentioned in a report posted on Analysis Sq. forward of peer assessment. “The excessive stage of antibodies shaped after the COVID-19 vaccination is usually interpreted because the effectiveness of a vaccine. We now perceive that whereas preliminary antibody response ranges can range throughout vaccines, their capability to forestall being hospitalized or dying from COVID-19 is equal,” panel member Dr. Erlina Burhan, a lung illness specialist on the College of Indonesia, in an announcement.

A spokesperson for the panelists mentioned the findings counsel decision-makers ought to use any vaccine kind that’s accessible and optimum for his or her native state of affairs, and that individuals who have a selection of vaccine ought to know that the one they will get quickest is greatest.

A separate examine revealed in Nature Communications discovered that whereas Moderna’s mRNA pictures present barely extra safety in opposition to coronavirus an infection than the Pfizer/BioNTech vaccine, “there are not any variations in vaccine effectiveness for defense in opposition to hospitalization, ICU admission, or dying/hospice switch.”

Click on for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in growth.